Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.
Pint Pharma has announced that Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted approval for Orladeyo (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks.
Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Mexico
Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil
Empaveli is the first treatment for PNH that binds to the complement protein C3.